However, the presence of B-rapidly accelerated fibrosarcoma (BRAF) mutations in PTC has been associated with reduced iodine avidity and a more aggressive clinical course, necessitating additional therapeutic approaches such as tyrosine kinase inhibitors or combination therapies targeting the mitogen-activated protein kinase and phosphoinositide 3-kinase/protein kinase B pathways [28, 29]. This evidence concerns the gene WNK2 and fibrosarcoma.